February 2024
1. VAN DER HELM-VAN MIL AHM
   Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
   Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
   

   >> Share

   
   
2. RECH J, Tascilar K, Hagen M, Kleyer A, et al
   Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02650-8. doi: 10.1016/S0140-6736(23)02650.
   

   >> Share

   
   
3. COPE AP, Jasenecova M, Vasconcelos JC, Filer A, et al
   Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02649-1. doi: 10.1016/S0140-6736(23)02649.
   

   >> Share

   
   November 2023
4. DI MATTEO A, Bathon JM, Emery P
   Rheumatoid arthritis.
   Lancet. 2023;402:2019-2033.
   

   >> Share

   
   June 2023
5. SAAVEDRA FT, Sierra LL, Zuluaica AM, Botero EC, et al
   Diagnosing Caplan syndrome in a patient with silicosis and rheumatoid arthritis: imaging shows miliary pattern and cavity lung lesions.
   Lancet. 2023;401:2148.
   

   >> Share

   
   May 2023
6. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
   Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
   Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
   

   >> Share

   
   February 2023
7. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
   Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
   Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
   

   >> Share

   
   September 2022
8. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
   Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
   Lancet. 2022;400:808-809.
   

   >> Share

   
   
9. DYBALL S, Parker B, Bruce IN
   Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
   Lancet. 2022;400:807-808.
   

   >> Share

   
   July 2022
10. KRIJBOLDER DI, Verstappen M, van Dijk BT, Dakkak YJ, et al
    Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial
    Lancet. 2022;400:283-294.
    

    >> Share

    
    
11. RECH J, Schett G
    Towards preventive treatment of rheumatoid arthritis.
    Lancet. 2022;400:253-255.
    

    >> Share

    
    January 2022
12. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    

    >> Share

    
    
13. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    

    >> Share

    
    August 2021
14. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share